Voyager Therapeutics (VYGR) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VYGR shares.
View VYGR analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1 year price objectives for Voyager Therapeutics' shares. Their VYGR share price forecasts range from $14.00 to $18.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price.
View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts.

Voyager Therapeutics' stock was trading at $6.10 on January 1st, 2023. Since then, VYGR stock has increased by 99.8% and is now trading at $12.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our VYGR earnings forecast.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings results on Tuesday, May, 9th. The company reported $2.94 earnings per share for the quarter, topping the consensus estimate of $0.15 by $2.79. The business earned $150.48 million during the quarter, compared to analysts' expectations of $99.33 million. Voyager Therapeutics had a negative net margin of 24.21% and a positive trailing twelve-month return on equity of 95.18%.

ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC),

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Voyager Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include EcoR1 Capital LLC (8.85%), Armistice Capital LLC (8.09%), Price T Rowe Associates Inc. MD (2.07%), BlackRock Inc. (1.89%), Farallon Capital Management LLC (1.83%) and Acadian Asset Management LLC (1.71%). Insiders that own company stock include Alfred Sandrock, Allison Dorval, Andre Turenne, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends.

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VYGR stock can currently be purchased for approximately $12.19.

Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $530.75 million and generates $40.91 million in revenue each year. The company earns $-46,410,000.00 in net income (profit) each year or $2.28 on an earnings per share basis.

The company employs 101 workers across the globe.

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.